Evidence map›Paper›PMID 39271966›Full record

ArticleOncogene2024

Correction: GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.

Hiroshi Ikeuchi, Yusuke Matsuno, Rika Kusumoto-Matsuo, Shinya Kojima, Toshihide Ueno, Masachika Ikegami, Rina Kitada, Hitomi Sumiyoshi-Okuma, Yuki Kojima, Kan Yonemori and 6 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Hiroshi IkeuchiDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Yusuke MatsunoLaboratory of Genome Stability Maintenance, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Rika Kusumoto-MatsuoLaboratory of Genome Stability Maintenance, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Shinya KojimaDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Toshihide UenoDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7408-7298
Masachika IkegamiDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Rina KitadaDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Hitomi Sumiyoshi-OkumaDepartment of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Yuki KojimaDepartment of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Kan YonemoriDepartment of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7624-7611
Yasushi YatabeDepartment of Diagnostic Pathology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.ORCID http://orcid.org/0000-0003-1788-559X
Kazuya TakamochiDepartment of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Kenji SuzukiDepartment of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Ken-Ichi YoshiokaLaboratory of Genome Stability Maintenance, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Hiroyuki ManoDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.ORCID http://orcid.org/0000-0003-4645-0181
Shinji KohsakaDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. skohsaka@ncc.go.jp.ORCID http://orcid.org/0000-0001-8651-6136

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39271966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.